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Objectives: Using a novel candidate SNP approach, we aimed to identify a possible
genetic basis for the higher glioma incidence in Whites relative to East Asians and
African-Americans. Methods: We hypothesized that genetic regions containing SNPs with
extreme differences in allele frequencies across ethnicities are most likely to harbor sus-
ceptibility variants. We used International HapMap Project data to identify 3,961 candidate
SNPs with the largest allele frequency differences in Whites compared to East Asians and
Africans and tested these SNPs for association with glioma risk in a set of White cases
and controls.Top SNPs identified in the discovery dataset were tested for association with
glioma in five independent replication datasets. Results: No SNP achieved statistical sig-
nificance in either the discovery or replication datasets after accounting for multiple testing
or conducting meta-analysis. However, the most strongly associated SNP, rs879471, was
found to be in linkage disequilibrium with a previously identified risk SNP, rs6010620, in
RTEL1. We estimate rs6010620 to account for a glioma incidence rate ratio of 1.34 for
Whites relative to East Asians. Conclusion: We explored genetic susceptibility to glioma
using a novel candidate SNP method which may be applicable to other diseases with
appropriate epidemiologic patterns.
Keywords: glioma, candidate SNP association study, ancestry informative markers, admixture, race, ethnicity, brain
cancer
INTRODUCTION
Incidence rates of adult primary malignant brain tumors (PMBT),
most of which are gliomas (Kohler et al., 2011), vary among eth-
nic groups (Darefsky and Dubrow, 2009; Dubrow and Darefsky,
2011). The age-standardized incidence rate for northern Amer-
ican non-Hispanic Whites is 2.5–3.0 times the rate among East
Asians and around twice the rate among African-Americans.
The latter ratio is likely to be higher for comparisons of White
to African populations, given the ∼20% European content of
the African-American genome (Patterson et al., 2004); however
presently there are no data allowing an evaluation (Darefsky and
Dubrow, 2009). These ethnic differences in PMBT incidence are
unlikely to be solely ascribable to factors such as access to care
or diagnostic facilities; in particular, the White-East Asian dif-
ference is observed in comparisons among different countries as
well as within the United States, where both groups have similar
access (Darefsky and Dubrow, 2009; Dubrow and Darefsky, 2011).
Notably, ethnic incidence variation has been observed for both
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grade IV glioma (glioblastoma, or GBM) and non-GBM tumors
(Dubrow and Darefsky, 2011).
The only established environmental risk factor for glioma is
exposure to high-dose ionizing radiation (Bondy et al., 2008;
Ostrom and Barnholtz-Sloan, 2011), which accounts for a small
number of cases; furthermore, studies have demonstrated a con-
sistent inverse association with history of allergy (Schoemaker
et al., 2010; Lachance et al., 2011) as well as evidence of inter-
action effects between history of allergy and several established
glioma risk alleles (Schoemaker et al., 2010). However, epi-
demiologic studies have provided no conclusive evidence for
diagnostic radiation (Davis et al., 2011), electromagnetic field
exposure from residential power lines (Wrensch et al., 1999),
smoking (Mandelzweig et al., 2009), alcohol consumption (Efird
et al., 2004), nutritional factors (Bondy et al., 2008), or cell
phone use (Cardis et al., 2010) as risk factors. Collectively, these
observations suggest that ethnic group associated genetic vari-
ants, rather than environmental factors, underscore variation in
glioma incidence among ethnic groups. Such an assertion is sup-
ported by a number of studies suggesting genetic pathways to
glioma may differ across ethnicities (Mochizuki et al., 1999; Chen
et al., 2001; Das et al., 2002; Wiencke et al., 2005). Following
on from this it is possible that the frequencies of haplotypes
associated with glioma susceptibility will differ between Whites
and East Asians/Africans, such that haplotypes harboring alle-
les associated with an increased glioma risk would be more
prevalent among Whites and conversely haplotypes associated
with decreased glioma risk would be more prevalent among East
Asians and Africans. Identification of these haplotypes offers the
prospect of gaining valuable insight into genes influencing glioma
risk.
Here we employed a candidate SNP approach to identify pre-
viously unknown genetic variants associated with glioma risk
through the identification of SNPs that may tag glioma-related
haplotypes. Our primary hypothesis is based on the premise that
the same alleles confer protection against glioma in both East
Asians and Africans. Consequently, we propose that these alleles
are carried at a greater frequency by both East Asians and Africans
than by Whites and that genetic regions (i.e., haplotypes) contain-
ing SNPs with the greatest allele frequency differences between
Whites and both East Asians and Africans (with the same direc-
tion of difference) are particularly likely to harbor these alleles. To
take into account the possibility that alleles that confer protection
in East Asians differ from alleles that confer protection in Africans,
we also propose a secondary hypothesis that genetic regions con-
taining SNPs with the greatest allele frequency differences between
Whites and either East Asians or Africans, but not both, are likely
to harbor protective alleles which are distinct from those identified
under the primary hypothesis.
Given that ethnic incidence differences are broadly similar for
GBM and non-GBM glioma (Dubrow and Darefsky, 2011), we
postulate that polymorphisms driving these incidence differences
are common across these glioma subtypes, and therefore consider
all gliomas combined without stratification. Since large differences
in allele frequency are needed to account for even a relatively small
portion of the White/East Asian or White/African incidence rate
ratio (Figure 1), we restrict our analyses to SNPs showing the
largest frequency differences.
FIGURE 1 | White/East Asian incidence rate ratios for varying allele
distributions and genotypic relative risks. Plots were generated by
calculating incidence rate ratios (IRRs) according to varying genotypic relative
risks (GRR) and ethnic group allele frequencies. For example, suppose the
GRR for glioma for persons with one B allele is 2.00, and the GRR for persons
with two B alleles is 3.00 (relative to those homozygous for the A allele). If the
frequency of allele A in Whites is 0.20 (p=0.2), the proportions of AA (p2), AB
(2pq), and BB (q2) genotypes are 0.04, 0.32, and 0.64, respectively, assuming
Hardy Weinberg equilibrium. To calculate a normalized incidence rate, the
genotype proportion is multiplied by the associated GRR risk: 0.04
(1.00)+0.32 (2.00)+0.64 (3.00)=2.60. Given an East Asian allele A frequency
of 0.80, the East Asian normalized incidence rate is 0.64 (1.00)+ 0.32
(2.00)+0.04 (3.00)=1.40. The White/East Asian IRR is 1.86 (2.60/1.40) in this
scenario. The same calculations apply for White/African IRRs.
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MATERIALS AND METHODS
SELECTION OF CANDIDATE SNPs
To select candidate SNPs we used allele frequency data on unre-
lated individuals from six populations included in the Interna-
tional HapMap Project Phase III (Altshuler et al., 2010): 113
Utah residents with Northern and Western European ethnicity
(CEU); 102 Toscans from Italy (TSI); 137 Han Chinese from
Beijing, China (CHB); 113 Japanese from Tokyo, Japan (JPT);
147 Yoruba from Ibadan, Nigeria (YRI); and 110 Luhya from
Webuye, Kenya (LWK). We grouped CEU and TSI together as
Whites, CHB and JPT as East Asians, and YRI and LWK as
Africans. Data from Phase III, release 28 were downloaded from
the HapMap Project File Transfer Protocol1. In this release, fre-
quency of genotype missingness per SNP was required to be
<0.05 per population, and SNPs were excluded with Hardy Wein-
berg P < 10−7. We used in-house Perl scripts to calculate allele
frequencies and call rates, according to ethnic group, for SNPs
genotyped previously for our discovery genome-wide associa-
tion study (GWAS) of high-grade adult glioma (Wrensch et al.,
2009). SNPs with call rates <95% among Whites, East Asians,
or Africans, respectively, were excluded. For each SNP, differ-
ences in reference allele frequencies were calculated for Whites vs.
East Asians and Whites vs. Africans, as well as the average differ-
ence if differences were in the same direction (e.g., the frequency
of allele A is low in Whites but high in both East Asians and
Africans).
To test our primary hypothesis, we selected SNPs with the great-
est average allele frequency differences (provided equivalent direc-
tionality) as defined by three categories:“Highest” (≥0.70),“High”
(0.60 to <0.70), and “Moderate” (0.40 to <0.60). To test our sec-
ondary hypothesis, we selected SNPs for which the allele frequency
difference was Highest (≥0.70) in one population comparison, but
Low (<0.40) in the other (“Highest/Low”).
DISCOVERY DATASET
Descriptive characteristics of discovery set cases and controls are
presented in Table 1. Subjects providing genotype data for the
1ftp://ftp.ncbi.nlm.nih.gov/hapmap
discovery phase included 692 high-grade glioma cases and 3,992
controls originally assembled for the 2009 GWAS of glioma by
Wrensch et al. (2009). Briefly, cases included 622 individuals of
European ethnicity from the San Francisco Adult Glioma Study
(AGS) and 70 from The Cancer Genome Atlas (TCGA; McLen-
don et al., 2008), aged 20 or older with incident histologically
confirmed anaplastic astrocytoma (n= 97) or GBM (n= 595;
International Classification of Diseases for Oncology, morphol-
ogy codes 9380–9481). Controls included 602 subjects from AGS
identified using random digit dialing and frequency matched to
cases on age, sex, and ethnicity, as well as 3,390 subjects from the
Illumina iControl Database2. All subjects were confirmed to be
unrelated and of European ethnicity by multidimensional scaling
analysis.
DISCOVERY DATASET GENOTYPING
Details of sample preparation and genotyping have been provided
previously (Wrensch et al., 2009). Briefly, DNA from all AGS cases
and controls was isolated from whole blood using Qiagen’s Gen-
tra Puregene DNA isolation kit, and genotyping was conducted
using Illumina’s HumanCNV370-Duo BeadChip. AGS samples
were required to have a call rate of at least 98%. SNPs deviat-
ing from Hardy Weinberg equilibrium in AGS or Illumina controls
(P < 10−5) were excluded from further analysis, as were those with
greater than 5% missing data in any of the four subject groups
(AGS cases or controls, TCGA cases, Illumina controls).
REPLICATION DATASETS
We investigated our top candidate SNPs from the discovery dataset
in five independent sets of cases and controls. Detailed procedures
of subject selection and genotyping have been described previ-
ously (Shete et al., 2009; Wrensch et al., 2009; Sanson et al., 2011).
Mayo Clinic cases (n= 176), 65% with GBM and 35% with grade
III glioma, were diagnosed in Rochester, Minnesota between 2005
and 2008. Controls (n= 174) were identified from among indi-
viduals who had a general medical exam at the Mayo Clinic, and
were matched to cases on sex, age, race, and residence. All cases
2http://www.illumina.com/science/icontroldb.ilmn
Table 1 | Discovery set subject characteristicsa.
Characteristicb Cases Controls
Adult Glioma
Study (n=622)
The Cancer Genome
Atlas (n=70)
Adult Glioma
Study (n=602)
Illumina iControls
(n=3,390)
Age 55±0.5 54±1.7 56±0.6 29±0.4
GENDER
Male 398 (64%) 40 (57%) 319 (53%) 1,254 (37%)
Female 224 (36%) 30 (43%) 283 (47%) 2,136 (63%)
TUMOR SUBTYPE
Grade III 97 (16%) 0 (0%) – –
Grade IV 525 (84%) 70 (100%) – –
aFrom Wrensch et al. (2009).
bTable values are mean± standard error for continuous variables and n (column%) for categorical variables.
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and controls were genotyped using Illumina Human 610Quad
arrays.
The four other replication datasets (UK, US, French, and Ger-
man) were previously included in a pooled GWAS of glioma (Shete
et al., 2009; Sanson et al., 2011). Briefly, the UK GWAS comprised
631 cases ascertained through the INTERPHONE study (Cardis
et al., 2010) and 2,699 controls from the 1958 Birth Cohort (Power
and Elliott, 2006). The US GWAS comprised 1,247 cases recruited
through MD Anderson Cancer Center in Houston, Texas and
2,236 controls from the Cancer Genetic Markers of Susceptibility
study (Hunter et al., 2007). The French GWAS comprised 1,423
cases from the Service de Neurologie Mazarin, Groupe Hospitalier
Pitié-Salpêtrière Paris, and 1,190 controls from the SU.VI.MAX
study (Hercberg et al., 2004). The German GWAS comprised
846 cases recruited from the University of Bonn Medical Center,
and 1,310 controls from the KORA (Holle et al., 2005; Wich-
mann et al., 2005), POPGEN (Krawczak et al., 2006), and Heinz
Nixdorf RECALL studies (Schmermund et al., 2002). Cases in
the UK and US GWAS were genotyped using Illumina Human
610Quad arrays, and cases from the French and German GWAS
were genotyped using Illumina HumanHap660 arrays. Controls
in the UK GWAS were genotyped using Illumina Human 1M
Duo arrays; the US controls on Illumina HumanHap240, 300,
and 500 arrays; the French controls on Illumina HumanHap660
arrays; and the German controls using Illumina HumanHap550
arrays.
STATISTICAL ANALYSES
Odds ratios and 95% confidence intervals for the association of
candidate SNPs with glioma in the discovery and replication sets
were calculated using unconditional logistic regression under an
additive model (0, 1, or 2 copies of the minor allele). Potential
population stratification was adjusted for using principal compo-
nents derived by the EIGENSTRAT method and included in the
logistic regression model (Price et al., 2006).
Discovery set results were evaluated in comparison to
Bonferroni-adjusted significance thresholds based on a study-wide
significance threshold of 0.05, calculated separately for each of the
four subgroups of candidate SNPs [Highest allele frequency dif-
ference (≥0.70), High (0.60 to <0.70), Moderate (0.40 to <0.60),
and Highest/Low (≥0.70 in one population, <0.40 in the other
population)] such that the significance thresholds accounted for
the prior probability of association with glioma according to
our hypotheses (i.e., P = 0.0125 per subgroup). With 38 SNPs in
the Highest allele frequency difference category, the significance
threshold for this category was 0.0125/38= 3.29× 10−4. Statis-
tical thresholds for the High, Moderate, and Highest/Low sub-
groups were 4.70× 10−5, 4.34× 10−6, and 1.61× 10−5, respec-
tively (Table 2). For replication set analyses we used a nominal
significance level of 0.05. All P-values reported (discovery and
replication) are one-sided because of the directionality inher-
ent in the hypothesis being tested. The generic inverse variance
method was used (assuming a fixed effects model) to obtain
meta-analysis results for combined discovery and replication set
data.
Analyses were conducted and data visualized using SAS soft-
ware version 9.2 (SAS Institute, Cary, NC, USA), Haploview
version 4.2 (Barrett et al., 2005), R version 2.13.1, Microsoft
Excel, Galaxy Project software (Blankenberg et al., 2001), and
Review Manager Version 5.1.4 (Cochrane Collaboration, Oxford,
UK).
RESULTS
SELECTED CANDIDATE SNPs
Of 275,895 SNPs for which genotype data on discovery glioma
cases and controls were previously available, HapMap data were
not available or were of insufficient quality for 1,188 (0.43%). Pre-
determined allele frequency difference criteria were met for 3,961
of the 274,707 remaining SNPs (Figure 2). We identified 2,883
SNPs in the Moderate (0.40 to <0.60) allele frequency difference
category, 266 in the High (0.60 to < 0.70) category, 38 in the
Highest (≥0.70) category, and 774 in the Highest/Low category
(≥0.70 in one population comparison, but <0.40 in the other;
Table 2; Figure 3).
DISCOVERY SET
A Manhattan plot of the 3,961 SNP-glioma associations is shown
in Figure 4. The most strongly associated SNP, rs879471 in STMN3
on chromosome 20q13 (P = 1.72× 10−4), maps 39.9 kb from
rs6010620, a SNP intronic to RTEL1 that was previously identi-
fied as a top hit in the GWAS conducted by Wrensch et al. (2009).
Conditioning rs879471 on rs6010620 did not, however, provide
evidence of a separate signal (P = 0.22), so rs879471 was excluded
from further analysis.
While no SNP association attained our predetermined
Bonferroni-adjusted significance levels (Table 2), 10 genes
(SMARCA2, BRE, SLCO3A1, MORN5, C10orf11, RBM27, PTPRJ,
SPIB, NMNAT1, and RPUSD3) were identified containing at least
one SNP with P < 0.01. In order to investigate SNPs that may
be markers of glioma risk but were excluded by our strict allele
frequency criteria, we tested 260 additional SNPs in these 10
genes and within 5 kb upstream and downstream for associa-
tion with glioma risk (regardless of ethnic allele frequency dif-
ferences). We excluded four genes (SLCO3A1, C10orf11, PTPRJ,
and NMNAT1) from further analysis because the direction of
Table 2 | Number of selected SNPs by allele frequency difference
category with corresponding Bonferroni-adjusted significance
thresholds.
Category Number
of SNPs
Significance
threshold
Primary
hypothesis
Highest mean allele
frequency difference
(≥0.70)
38 3.29×10−4
High mean allele frequency
difference (0.60 to <0.70)
266 4.70×10−5
Moderate mean allele
frequency difference (0.40
to <0.60)
2,883 4.34×10−6
Secondary
hypothesis
Highest/low allele
frequency differences
(≥0.70 in one comparison
and <0.40 in the other)
774 1.61×10−5
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FIGURE 2 | Flow diagram of candidate SNP selection from HapMap.
FIGURE 3 | White vs. African and White vs. East Asian allele frequency
differences and selected candidate SNPs. Each SNP is plotted by its allele
frequency difference between Whites and Africans vs. its allele frequency
difference between Whites and East Asians. Green SNPs in the upper-right and
lower-left quadrants represent those with mean allele frequency differences of
0.40 to <0.60 (Moderate), red SNPs represent those with mean allele
frequency differences of 0.60 to <0.70 (High), and black SNPs represent those
with mean allele frequency differences ≥0.70 (Highest). Orange SNPs around
the perimeter represent those in which the allele frequency difference was at
least 0.70 in one comparison, but less than 0.40 in the other (Highest/Low).
www.frontiersin.org October 2012 | Volume 3 | Article 203 | 5
Jacobs et al. Ethnicity and glioma risk
FIGURE 4 | Manhattan plot for 3,961 tested candidate SNPs.
association of additional tested SNPs with glioma risk was incon-
sistent with our hypothesis. All SNPs with P < 0.01 across the
six remaining genes (SMARCA2, BRE, MORN5, RBM27, SPIB,
and RPUSD3) were selected for replication (n= 20 SNPs, nine
of which were identified in the secondary discovery analy-
sis).
REPLICATION SETS
Discovery and replication set results for the 20 selected SNPs
are presented in Table 3. Genotype data were not available for
rs4464229 or rs3863 in the UK, US, French, or German sets, and
data were not available for rs4666022 in any of the replication
sets. For the remaining SNPs, four achieved nominal significance
(P < 0.05) with an odds ratio in the same direction as in the discov-
ery set in one of the five replication sets and one achieved nominal
significance in two of the replication sets; however, none achieved
statistical significance in a replication set after correcting for mul-
tiple comparisons, and none achieved nominal significance in the
meta-analysis.
DISCUSSION
Here we have applied a novel candidate SNP method to iden-
tify glioma risk alleles, taking advantage of ethnic group differ-
ences in glioma incidence. Specifically, we tested the hypothesis
that genetic regions containing SNPs with extreme differences
in allele frequencies across ethnicities harbor variants that drive
the ethnic group variation in glioma incidence. Although in the
present study no SNPs from our discovery set reached our pre-
determined significance thresholds, we identified 10 genes con-
taining one or more SNPs with P < 0.01, and selected 20 SNPs
across six genes for replication. However, no SNP was statistically
significant in any of the replication sets after accounting for mul-
tiple comparisons, and no SNP was nominally significant in the
meta-analysis.
There were some limitations of this study which may have pre-
vented the detection of glioma-associated SNPs. While our allele
frequency difference criteria for candidate SNPs were designed
to be inclusive of SNPs that could be responsible for a mean-
ingful risk difference across ethnic groups, it is possible that
these criteria excluded SNPs that are, in fact, associated with
glioma risk but did not meet our criteria. Additionally, given
692 cases and 3,992 controls in our discovery set, our power
calculations demonstrate that for a moderately common puta-
tive risk allele (0.20 allele frequency), we had 80% power to
detect an odds ratio as low as 1.46. Yet for a relatively rare risk
allele (0.05 allele frequency), we had 80% power to detect an
odds ratio no lower than 1.88. Thus, it is plausible that our set
of candidate SNPs includes one or more variants with low to
moderate association with glioma risk, but that we were under-
powered to detect such an association. Furthermore, it should be
noted that although we postulated that polymorphisms driving
ethnic group incidence differences are common across glioma
subtypes, it is possible that differences in the glioma subtype
distribution in the discovery and replication sets impacted the
replicability of our findings. The ability of our approach to
detect SNPs that tag glioma-related haplotypes may also have
been degraded by heterogeneity across ethnic groups in the hap-
lotype that a given tagging SNP represents. Finally, we note
that our study was unable to assess potential interaction effects
between risk loci, gene-environment interactions, or the role of
rare variants.
Although this study did not lead to the discovery of novel
glioma-associated SNPs, it is noteworthy that our most strongly
associated candidate SNP, rs879471, was in strong linkage
disequilibrium with rs6010620 (D′= 0.78 in HapMap CEU+TSI,
data from Haploview version 4.2), a top hit from the Wrensch
et al. (2009) GWAS. This suggests the successful identification of
a haplotype that differs in frequency across ethnic groups and
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Table 4 | Contribution to ethnic incidence rate ratios by established glioma susceptibility loci.
SNP Reference
allele
Reference allele frequency Odds ratio (95%
confidence interval)a
White-East Asian
incidence rate ratio
White-African incidence
rate ratio
White East Asian African
rs6010620 A 0.23 0.70 0.02 0.68 (0.58, 0.79)b 1.34 0.90
rs1412829 C 0.40 0.10 0.01 1.39 (1.24, 1.57)b 1.22 1.30
rs2736100 G 0.54 0.41 0.42 1.27 (1.19, 1.37)c 1.05 1.05
rs4295627 G 0.15 0.24 0.16 1.36 (1.29, 1.43)c 0.95 0.99
rs4977756 G 0.37 0.23 0.34 1.24 (1.19, 1.30)c 1.06 1.01
rs498872 T 0.28 0.24 0.08 1.18 (1.13, 1.24)c 1.01 1.07
rs2252586 T 0.28 0.02 0.32 1.18 (1.11, 1.25)d 1.09 0.99
aOdds ratios were calculated according to an additive model (0, 1, or 2 copies of the reference allele).
bWrensch et al. (2009).
cShete et al. (2009).
dSanson et al. (2011).
is related to glioma risk. In this respect the A allele of rs6010620,
which is protective against glioma (OR= 0.68, 95% CI: 0.58–0.79),
is considerably more common in East Asians than Whites (fre-
quency of 0.697 vs. 0.228, respectively), but did not meet our
strict allele frequency difference criteria because the frequency
in Africans was 0.019. On the basis of a calculation similar to
that presented in Figure 1, we would conclude that this SNP
is sufficient to account for an incidence rate ratio of 1.34 for
Whites relative to East Asians. Notably, another top hit from the
same GWAS, rs1412829, has a risk allele C (OR= 1.39, 95% CI:
1.24–1.57) that is more common in Whites than East Asians or
Africans but also did not meet our allele frequency criteria (fre-
quency of 0.402, 0.104, and 0.009, respectively). Based on our
calculations, this SNP can account for a White to East Asian
incidence rate ratio of 1.22, and a White to African incidence
rate ratio of 1.30. Thus, these two SNPs alone may account for
a meaningful proportion of the observed inter-ethnic incidence
rate ratios. None of the other five established glioma susceptibil-
ity loci contribute to the inter-ethnic incidence rate differences
(Table 4).
The candidate SNP approach used in this study provides a
viable alternative to admixture mapping, which investigates the
genetic makeup of recently admixed groups to localize disease-
related variants (Patterson et al., 2004; Smith and O’Brien, 2005).
In the context of glioma research, the admixture method would
ideally be applied to a set of African-American cases and controls,
where excess European ethnicity shared among African-American
cases would be suggestive of genetic regions that may play a role
in glioma risk. For conditions like hypertension, where prevalence
differs widely between ethnicities and samples from an admixed
group are available, the pairing of admixture mapping with GWAS
has proven to be an effective means of identifying disease-related
variants (Levy et al., 2009; Zhu et al., 2011). However, when sam-
ples from an admixed group are not available, we present our
approach as an alternative complement to GWAS. Specifically,
this approach to identify disease-causing variants is attractive
where (1) the disease incidence differs substantially across two
or more ethnic groups; (2) ethnic group differences tend to persist
independent of geographic location, suggesting a genetic etiol-
ogy; (3) there is an availability of cases and controls of uniform
ethnicity; and (4) an admixture approach is not feasible given
the unavailability of a sufficient number of appropriate admixed
cases.
While we did not identify novel glioma susceptibility variants
in this analysis, we conclude that the additional risk in White pop-
ulations conferred by rs6010620 and rs1412829 lends support to
our initial hypothesis, and provides an impetus for a larger dis-
covery set and/or pursuing admixture mapping. Given the rarity
of glioma among African-Americans and the resultant difficulties
inherent in collecting enough African-American cases to perform
an admixture mapping study, further application of our method
may be the preferred approach.
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